The government is preparing to extend Palantir’s £330m contract to run the NHS Federated Data Platform by up to two years while it develops a new procurement intended to give a British supplier the opportunity to take over. The proposed extension has not been publicly confirmed, but would keep the US company running part of the NHS’s data infrastructure beyond the contract’s March 2027 review point.
The reported plan follows a review that judged replacing Palantir within four months impractical. Ministers had until 12 December to exercise a break clause in the agreement, making the decision about whether to end or extend the existing arrangement a more immediate question than the eventual choice of a replacement.
The platform sits across NHS trusts and holds operational data used for waiting lists and discharge planning. The contract therefore concerns not only the purchase of technology, but also who runs systems used to organise NHS care and how claims about their performance are checked.
A two-year option in the existing contract
Palantir signed the three-year contract in 2023. Worth £330m, it includes an option for a two-year extension, followed by two further one-year periods. The proposed extension would use the first of those options rather than immediately replacing the supplier at the March 2027 review point.
An extension of up to two years is not the same as a decision to use every available option. There is no confirmed announcement that the subsequent one-year periods would be taken up, or that Palantir would remain the supplier beyond the proposed extension.
The reported conclusion that a replacement could not practically be put in place within four months underpins the plan to continue the current arrangement. It does not, by itself, establish that Palantir is the only company capable of running the platform over the longer term.
Ministers hope a new procurement will lead to a British supplier taking over. British firms are expected to bid when the contract is retendered, although that expectation is not a guarantee that a domestic company will win the work.
Ministers have yet to confirm the decision
Health Secretary Yvette Cooper declined to confirm the decision when she appeared before the Health and Social Care Committee. The Department of Health and Social Care pointed to its earlier statements that the review would be announced in the normal way.
That leaves an important distinction between the reported preparations and a formally announced contract decision. The duration of any extension, and the arrangements for the next procurement, remain matters for the government to confirm.
The proposed approach would separate the immediate need to retain an operating platform from the longer-term ambition to change its supplier. Palantir would continue under the existing agreement while the government designs a competition for the next contract.
It also tests the government’s stated preference for sovereign British technology. An extension would leave a US company in place for longer, even as ministers seek a procurement that could transfer responsibility to a British firm. The eventual outcome would depend on that competition, not simply on the government’s preference.
Claims about operations and discharge delays face scrutiny
The contract decision follows months of scrutiny of the platform’s claimed benefits and patient objections to data use. Those issues are distinct from the practical question of how quickly a different supplier could take over, but remain relevant to the assessment of the platform.
Palantir has claimed that the platform contributed to more than 100,000 additional operations and a 14 per cent reduction in discharge delays. These are the company’s claims, rather than independently established outcomes in the information available.
The Office for Statistics Regulation raised concerns over the summer about contested figures used to promote the platform. The concerns mean the headline numbers should not be treated as settled evidence of what the system has delivered.
NHS England chief executive Sir Jim Mackey told MPs that suppliers must clear claims about benefits with the health service before publishing them. That requirement places NHS England in a checking role before suppliers make public statements about results attributed to their systems.
Retender will determine the longer-term supplier
The next formal step is an announcement of the government’s review. Until then, the extension remains unconfirmed, and the reported plan should not be treated as a completed agreement.
If it proceeds, the extension would preserve Palantir’s role while a retender is prepared. That competition would determine who runs the platform next. Alongside the choice of supplier, scrutiny of data use and the evidence behind claimed benefits will remain central to the debate over its place in the NHS.
